ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)

This publication has 246 references indexed in Scilit:

• Structural basis of interleukin‐5 dimer recognition by its α receptor
  Protein Science, 2012
• Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy
  Pediatric Nephrology, 2011
• Recent advances in the IL-17 cytokine family
  Current Opinion in Immunology, 2011
• Complement and viral pathogenesis
  Virology, 2011
• Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels
  Journal of Allergy and Clinical Immunology, 2008
• Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
  The Lancet, 2008
• Protective immune mechanisms in helminth infection
  Nature Reviews Immunology, 2007
• Anti-IgE treatment of eosinophil-associated gastrointestinal disorders
  Journal of Allergy and Clinical Immunology, 2007
• Evaluation and Differential Diagnosis of Marked, Persistent Eosinophilia
  Immunology and Allergy Clinics of North America, 2007
• Long‐term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin‐1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double‐blind, placebo‐controlled trial
  Arthritis & Rheumatism, 2002